Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yasuo Harigaya is active.

Publication


Featured researches published by Yasuo Harigaya.


Science | 1996

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Karen Hsiao; Paul F. Chapman; Steven P. Nilsen; Chris Eckman; Yasuo Harigaya; Steven G. Younkin; Fusheng Yang; Greg M. Cole

Transgenic mice overexpressing the 695-amino acid isoform of human Alzheimer β-amyloid (Aβ) precursor protein containing a Lys670 → Asn, Met671 → Leu mutation had normal learning and memory in spatial reference and alternation tasks at 3 months of age but showed impairment by 9 to 10 months of age. A fivefold increase in Aβ(1–40) and a 14-fold increase in Aβ(1–42/43) accompanied the appearance of these behavioral deficits. Numerous Aβ plaques that stained with Congo red dye were present in cortical and limbic structures of mice with elevated amounts of Aβ. The correlative appearance of behavioral, biochemical, and pathological abnormalities reminiscent of Alzheimers disease in these transgenic mice suggests new opportunities for exploring the pathophysiology and neurobiology of this disease.


Acta Neuropathologica | 1988

Diffuse type of senile plaques in the brains of Alzheimer-type dementia

Haruyasu Yamaguchi; Shunsaku Hirai; M. Morimatsu; Mikio Shoji; Yasuo Harigaya

SummaryWe studied the nature of diffuse type of senile plaques (SP) in the brains of six autopsied subjects with Alzheimer-type dementia (ATD). The densities of SP in the entorhinal cortex were evaluated using serial sections stained by four different methods. Compared with β protein immunostaining (100% as a reference), the modified Bielschowsky stain (103%) and the periodic acid-methenamine silver (PAM) stain (109%) labeled similar numbers of SP, whereas the Bodian stain labeled only a minor proportion (42%) of these. The vast majority of Bodian-negative plaques were diffuse plaques, which were seen as ill-defined areas of fine fibrillar material after β protein immunostain with formic acid pretreatment, modified Bielschowsky stain, and PAM stain. They were not stained by Congo red or periodic acid-Schiff stains. Double staining using Bodian and β protein methods demonstrated that diffuse plaques were free of swollen neurites. Argyrophilia of the diffuse plaques shown by the modified Bielschowsky and PAM stains, became undetectable when sections were pretreated with formic acid. Such treatment made the diffuse plaques immunoreactive to β protein antiserum, suggesting that diffuse plaques consisted mainly of amyloid, but not neuritic components. The diffuse plaques were distributed in various cortical areas and in the amygdala, and comprised a considerable population of the SP in the ATD brains.


Journal of the Neurological Sciences | 1998

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Mikio Shoji; Etsuro Matsubara; Mitsuyasu Kanai; Mitsunori Watanabe; Tamiko Nakamura; Yasushi Tomidokoro; Masami Shizuka; Katsumi Wakabayashi; Yukifusa Igeta; Yoshio Ikeda; Kazuyuki Mizushima; Masakuni Amari; Koji Ishiguro; Takeshi Kawarabayashi; Yasuo Harigaya; Koich Okamoto; Shunsaku Hirai

Cerebrospinal fluid samples from a total of 157 subjects consisting of 55 patients with sporadic Alzheimers disease (AD), 34 normal controls, 23 patients with non-AD dementia, and 45 with other neurological diseases were examined by ELISA of tau, Aβ1-40, and Aβ1-42(43). The AD group had a significantly higher level of tau than the normal control group (P<0.001), and the diagnostic sensitivity was 31% and specificity was 94%. CSF Aβ1-40 levels did not show any significant differences. Although the level of Aβ1-42(43) was decreased significantly in the AD group compared to the control group (P<0.005), the overlap of Aβ1-42(43) levels among all groups meant that none of the AD samples exceeded the cut-off value, the mean 2SD of normal control subjects. Reduction of Aβ1-42(43) levels in AD resulted in a significant increase in the ratio of Aβ1-40 to Aβ1-42(43) (Aβ ratio) as an improved marker. The diagnostic sensitivity and specificity of Aβ ratio were 51% and 82% respectively. The three indexes, using the tau level and Aβ ratio (tau or Aβ ratio, deviation score and tau×Aβ ratio), showed better sensitivity (58%, 67%, 69%) and specificity (82%, 86%, 88%) than previously reported methods. Combination assay for CSF tau, Aβ1-40 and Aβ1-42(43) in CSF is a biological marker of AD and may be useful to biochemically monitor subjects under treatment.


Brain Research | 1991

Expression of APP in the early stage of brain damage

Takeshi Kawarabayashi; Mikio Shoji; Yasuo Harigaya; Haruyasu Yamaguchi; Shunsaku Hirai

We immunocytochemically studied the expression of various epitopes of amyloid beta/A4 protein precursor (APP) after brain damage by kainic acid injection. After 3 h, APP695 rapidly accumulated in dystrophic neurites near the damaged site. After 3 days, APP with Kunitz-type protease inhibitor domain was expressed in reactive astrocytes in the lesion and ipsilateral hippocampus. APP rapidly accumulated in dystrophic neurites, and different types of APP were expressed in different cell types in the damaged brain.


Annals of Neurology | 2004

Pael-R is accumulated in Lewy bodies of Parkinson's disease.

Tetsuro Murakami; Mikio Shoji; Yuzuru Imai; Haruhisa Inoue; Takeshi Kawarabayashi; Etsuro Matsubara; Yasuo Harigaya; Atsushi Sasaki; Ryosuke Takahashi; Koji Abe

We examined the distribution of Pael‐R, a newly identified substrate for Parkin, in Parkinsons disease (PD) and multiple system atrophy (MSA). Pael‐R, Parkin, α‐synuclein, and ubiquitin accumulated in Lewy bodies (LBs) and neurites. Pael‐R was localized in the core of LBs. Parkin and α‐synuclein accumulated in the halo, neuronal cell bodies, and processes. These findings potentially suggest the involvement of Pael‐R in LB formation, and protection role of Parkin in Pael‐R‐mediated neurotoxicity in PD. The absence of Pael‐R and Parkin in glial cytoplasmic inclusions (GCIs) in MSA implies a distinct pathway involved in the formation of LBs and GCIs. Ann Neurol 2004


Neuroscience Letters | 2001

Aβ amyloidosis induces the initial stage of tau accumulation in APPSW mice

Yasushi Tomidokoro; Koichi Ishiguro; Yasuo Harigaya; Etsuro Matsubara; Masaki Ikeda; Jung-Mi Park; Kaori Yasutake; Takeshi Kawarabayashi; Koichi Okamoto; Mikio Shoji

Abstract To clarify how Aβ deposits induce secondary tauopathy, the presence of phosphorylated tau, glycogen synthase kinase 3α (GSK3α), GSK3β, cyclin-dependent kinase 5 (CDK5), mitogen-activated protein kinase (MAPK) and fyn were examined in the Tg2576 brain showing substantial brain Aβ amyloidosis and behavioral abnormalities. Phosphorylated tau at Ser199, Thr231/Ser235, Ser396 and Ser413 accumulated in the dystrophic neurites of senile plaques. The major kinase for tau phosphorylation was GSK3β. Smaller contributions of GSK3α, CDK5 and MAPK were suggested. Thus, brain Aβ amyloidosis has a potential role in the induction of tauopathy leading to the mental disturbances of Alzheimers disease.


Annals of Neurology | 1999

Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome

Etsuro Matsubara; Jorge Ghiso; Blas Frangione; Masakuni Amari; Yasushi Tomidokoro; Yoshio Ikeda; Yasuo Harigaya; Koichi Okamoto; Mikio Shoji

About 90% of the soluble amyloid β (sAβ) that circulates in normal human plasma is associated with lipoprotein particles. In sporadic Alzheimers disease patients, free sAβ42 but not sAβ40 is increased approximately 2.3‐fold compared with age‐matched controls, although a more marked elevation (approximately 8‐fold for free sAβ40 and about 20‐fold for sAβ42) is found in Downs syndrome patients. The data suggest that lipoprotein‐sAβ dissociation may contribute to the influx of sAβ into the brain as a result of decreased plasma clearance. Ann Neurol 1999;45:537–541


American Journal of Pathology | 2005

Accumulation of Filamentous Tau in the Cerebral Cortex of Human Tau R406W Transgenic Mice

Masaki Ikeda; Mikio Shoji; Toshitaka Kawarai; Takeshi Kawarabayashi; Etsuro Matsubara; Tetsuro Murakami; Atsushi Sasaki; Yasushi Tomidokoro; Yasushi Ikarashi; Hisashi Kuribara; Koichi Ishiguro; Masato Hasegawa; Shu Hui Yen; M. Azhar Chishti; Yasuo Harigaya; Koji Abe; Koichi Okamoto; Peter St George-Hyslop; David Westaway

Missense mutations of the tau gene cause autosomal dominant frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), an illness characterized by progressive personality changes, dementia, and parkinsonism. There is prominent frontotemporal lobe atrophy of the brain accompanied by abundant tau accumulation with neurofibrillary tangles and neuronal cell loss. Using a hamster prion protein gene expression vector, we generated several independent lines of transgenic (Tg) mice expressing the longest form of the human four-repeat tau with the R406W mutation associated with FTDP-17. The TgTauR406W 21807 line showed tau accumulation beginning in the hippocampus and amygdala at 6 months of age, which subsequently spread to the cortices and subcortical areas. The accumulated tau was phosphorylated, ubiquitinated, conformationally changed, argyrophilic, and sarcosyl-insoluble. Activation of GSK-3beta and astrocytic induction of mouse tau were observed. Astrogliosis and microgliosis correlated with prominent tau accumulation. Electron microscopic examination revealed the presence of straight filaments. Behavioral tests showed motor disturbances and progressive acquired memory loss between 10 to 12 months of age. These findings suggested that TgTauR406W mice would be a useful model in the study of frontotemporal dementia and other tauopathies such as Alzheimers disease (AD).


PLOS ONE | 2013

SORL1 Is Genetically Associated with Late-Onset Alzheimer’s Disease in Japanese, Koreans and Caucasians

Akinori Miyashita; Asako Koike; Gyungah Jun; Li-San Wang; Satoshi Takahashi; Etsuro Matsubara; Takeshi Kawarabayashi; Mikio Shoji; Naoki Tomita; Hiroyuki Arai; Takashi Asada; Yasuo Harigaya; Masaki Ikeda; Masakuni Amari; Haruo Hanyu; Susumu Higuchi; Takeshi Ikeuchi; Masatoyo Nishizawa; Masaichi Suga; Yasuhiro Kawase; Hiroyasu Akatsu; Kenji Kosaka; Takayuki Yamamoto; Masaki Imagawa; Tsuyoshi Hamaguchi; Masahito Yamada; Takashi Moriaha; Masatoshi Takeda; Takeo Takao; Kenji Nakata

To discover susceptibility genes of late-onset Alzheimer’s disease (LOAD), we conducted a 3-stage genome-wide association study (GWAS) using three populations: Japanese from the Japanese Genetic Consortium for Alzheimer Disease (JGSCAD), Koreans, and Caucasians from the Alzheimer Disease Genetic Consortium (ADGC). In Stage 1, we evaluated data for 5,877,918 genotyped and imputed SNPs in Japanese cases (n = 1,008) and controls (n = 1,016). Genome-wide significance was observed with 12 SNPs in the APOE region. Seven SNPs from other distinct regions with p-values <2×10−5 were genotyped in a second Japanese sample (885 cases, 985 controls), and evidence of association was confirmed for one SORL1 SNP (rs3781834, P = 7.33×10−7 in the combined sample). Subsequent analysis combining results for several SORL1 SNPs in the Japanese, Korean (339 cases, 1,129 controls) and Caucasians (11,840 AD cases, 10,931 controls) revealed genome wide significance with rs11218343 (P = 1.77×10−9) and rs3781834 (P = 1.04×10−8). SNPs in previously established AD loci in Caucasians showed strong evidence of association in Japanese including rs3851179 near PICALM (P = 1.71×10−5) and rs744373 near BIN1 (P = 1.39×10−4). The associated allele for each of these SNPs was the same as in Caucasians. These data demonstrate for the first time genome-wide significance of LOAD with SORL1 and confirm the role of other known loci for LOAD in Japanese. Our study highlights the importance of examining associations in multiple ethnic populations.


Brain Research | 1990

Amyloid β-protein precursor accumulates in dystrophic neurites of senile plaques in Alzheimer-type dementia

Mikio Shoji; Shunsaku Hirai; Haruyasu Yamaguchi; Yasuo Harigaya; Takeshi Kawarabayashi

Abstract We raised two rabbit antisera against synthetic peptides corresponding to the car☐yl- and amino-terminal regions of the predicted amyloid β-protein precursor (APP). Both antisera recognized the same 106–135 kDa proteins of human brain extract by immunoblot analysis. Immunocytochemical studies showed that these antisera both reacted with the same dystrophic neurites within the senile plaques of Alzheimer brains. These results indicated that APP accumulated in the dystrophic neurites of the senile plaques.

Collaboration


Dive into the Yasuo Harigaya's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge